Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025
Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025
Unity Biotechnology的2023年現金、現金等價物和有價證券的4,320萬美元預計將爲2025年第三季度的運營提供資金
Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025
Unity Biotechnology的2023年現金、現金等價物和有價證券的4,320萬美元預計將爲2025年第三季度的運營提供資金
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。